These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 25165170)

  • 1. Paliperidone depot is not different from haloperidol in relapse prevention of schizophrenia, but different side effects should be considered.
    Freudenreich O
    Evid Based Ment Health; 2014 Nov; 17(4):110. PubMed ID: 25165170
    [No Abstract]   [Full Text] [Related]  

  • 2. Antipsychotic medications for schizophrenia.
    Fleischhacker WW
    JAMA; 2014 Oct; 312(14):1467-8. PubMed ID: 25291585
    [No Abstract]   [Full Text] [Related]  

  • 3. Antipsychotic medications for schizophrenia.
    Suzuki T
    JAMA; 2014 Oct; 312(14):1468-9. PubMed ID: 25291586
    [No Abstract]   [Full Text] [Related]  

  • 4. Antipsychotic medications for schizophrenia--reply.
    Stroup TS; McEvoy JP; Hamer RM
    JAMA; 2014 Oct; 312(14):1469. PubMed ID: 25291588
    [No Abstract]   [Full Text] [Related]  

  • 5. Maintenance treatment with long-acting injectable antipsychotics: comparing old with new.
    Goff DC
    JAMA; 2014 May; 311(19):1973-4. PubMed ID: 24846032
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia: A Randomized Clinical Trial.
    Berwaerts J; Liu Y; Gopal S; Nuamah I; Xu H; Savitz A; Coppola D; Schotte A; Remmerie B; Maruta N; Hough DW
    JAMA Psychiatry; 2015 Aug; 72(8):830-9. PubMed ID: 25820612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paliperidone palmitate for refractory and clozapine-resistant schizophrenia.
    Maia-de-Oliveira JP; Nunes EA; Ushirohira JM; Machado-de-Sousa JP; Bressan RA; Hallak JE
    J Neuropsychiatry Clin Neurosci; 2015; 27(1):e14-6. PubMed ID: 25716490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paliperidone palmitate for schizophrenia.
    Nussbaum AM; Stroup TS
    Schizophr Bull; 2012 Nov; 38(6):1124-7. PubMed ID: 22966147
    [No Abstract]   [Full Text] [Related]  

  • 9. Design and rationale of the Paliperidone Palmitate Research in Demonstrating Effectiveness (PRIDE) study: a novel comparative trial of once-monthly paliperidone palmitate versus daily oral antipsychotic treatment for delaying time to treatment failure in persons with schizophrenia.
    Alphs L; Mao L; Rodriguez SC; Hulihan J; Starr HL
    J Clin Psychiatry; 2014 Dec; 75(12):1388-93. PubMed ID: 25375367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacoeconomics of depot antipsychotics for treating chronic schizophrenia in Sweden.
    Einarson TR; Vicente C; Zilbershtein R; Piwko C; Bø CN; Pudas H; Jensen R; Hemels ME
    Nord J Psychiatry; 2014 Aug; 68(6):416-27. PubMed ID: 24274837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost effectiveness of paliperidone palmitate for the treatment of schizophrenia in Germany.
    Zeidler J; Mahlich J; Greiner W; Heres S
    Appl Health Econ Health Policy; 2013 Oct; 11(5):509-21. PubMed ID: 23975630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tardive dyskinesia induced by a switch from haloperidol depot to paliperidone palmitate.
    Hsu CY; Lin YH; Shen YC
    J Neuropsychiatry Clin Neurosci; 2013; 25(4):E46-7. PubMed ID: 24247889
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of acute paliperidone palmitate treatment in subjects with schizophrenia recently treated with oral risperidone.
    Sliwa JK; Bossie CA; Ma YW; Alphs L
    Schizophr Res; 2011 Oct; 132(1):28-34. PubMed ID: 21775106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of an economic model of paliperidone palmitate for chronic schizophrenia.
    Einarson TR; Hemels ME
    J Med Econ; 2013 Nov; 16(11):1267-74. PubMed ID: 24003857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paliperidone palmitate in a child with autistic disorder.
    Kowalski JL; Wink LK; Blankenship K; Habenicht CD; Erickson CA; Stigler KA; McDougle CJ
    J Child Adolesc Psychopharmacol; 2011 Oct; 21(5):491-3. PubMed ID: 22040196
    [No Abstract]   [Full Text] [Related]  

  • 16. Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimens.
    Fu DJ; Bossie CA; Kern Sliwa J; Ma YW; Alphs L
    Clin Schizophr Relat Psychoses; 2014 Jul; 8(2):101-9, 109A. PubMed ID: 23446197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolonged elimination of paliperidone after administration of paliperidone palmitate depot injections.
    Helland A; Syrstad VE; Spigset O
    J Clin Psychopharmacol; 2015 Feb; 35(1):95-6. PubMed ID: 25478938
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia.
    Emsley R; Nuamah I; Hough D; Gopal S
    Schizophr Res; 2012 Jun; 138(1):29-34. PubMed ID: 22446143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paliperidone palmitate versus oral risperidone and risperidone long-acting injection in patients with recently diagnosed schizophrenia: a tolerability and efficacy comparison.
    Fu DJ; Bossie CA; Sliwa JK; Ma YW; Alphs L
    Int Clin Psychopharmacol; 2014 Jan; 29(1):45-55. PubMed ID: 24113628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Onset and persistence of efficacy by symptom domain with long-acting injectable paliperidone palmitate in patients with schizophrenia.
    Alphs L; Bossie CA; Fu DJ; Ma YW; Kern Sliwa J
    Expert Opin Pharmacother; 2014 May; 15(7):1029-42. PubMed ID: 24754314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.